Clinical Trial Search

Primary: Number of Participants With Any On-treatment Adverse Event (AE) or Any Serious Adverse Event (SAE) — 57; 132; 120; 7 Participants

Primary: Microbiological Efficacy of Gentamicin and Azithromycin for the Treatment of Uncomplicated Gonococcal Infection — 100 percentage of participants — p=<0.05

Primary: Upper Extremity Portion of the Fugl-Meyer Motor Performance Assessment — 3.27; 2.51; 1.82 units on a scale — p=.025

Primary: Area Under Curve (AUC) (0-24) of Abacavir on Twice Daily Dosing — 10.85 h*mg/L

Primary: Glycosylated Hemoglobin A1C (HbA1c) at Endpoint — 7.50; 7.40 percentage of glycosylated hemoglobin

Primary: Reliability of the Respiratory Domain of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) — 0.80 Intraclass Correlation Coefficient

Primary: Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants — -1.98; -1.45; -1.44…

Primary: Difference in Salivary Flow Rate (ml/Min) Between Study Groups — .072; .003; NA ml/min

Primary: Drinks Per Drinking Day — 8.7; 8.9; 9.2 Drinks per drinking day

Primary: Positive and Negative Symptom Scale (PANSS) Total Score at Baseline — 94.74; 94.24; 96.88; 101.33 units on a scale

Primary: Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years — 38; 48 percentage of participants

Primary: The Percent Change From Baseline in Bone Mineral Density (BMD) at Total Hip — -1.46; -3.19 percentage change — p=0.001

Primary: Progression Free Survival Rate at 12 Weeks — 46 percentage of participants

Primary: Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters — 311; 269; 34; 6 participants

Primary: Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters. — 126; 112; 17; 12 participants